Gabather AB

Company | Sweden

About your organization

Gabather AB is a Swedish Pharma/Biotech Company focused on the development of novel medicines for the treatment of mental disorders with high unmet medical need, such as schizophrenia. Our most advanced compound GT-002 is a novel first in class agent targeting three central aspects of mental disorders; i) inhibits psychosis; ii) improves memory and cognition and iii) promotes social interaction counteracting the debilitating social withdrawal accompanying many central nervous system (CNS) diseases. This differentiates GT-002 from all other therapies on the market, which are only able to target a limited range of symptoms in e.g. schizophrenia focusing primarily on psychosis and other associated positive symptoms. GT-002 is currently in clinical phase I development and targeted for proof of concept (POC) clinical studies in patients during 2020.

The commercialisation strategy is to develop GT-002 to clinical Phase II POC and thereafter acquire strategic partners for continued clinical development and market launch.

Gabather aims to gain global recognition as an emerging knowledge centre for treatment of schizophrenia and then expand to other mental disorders, including autism spectrum disorder (ASD), bipolar disorder, attentional deficit hyperactivity disorder (ADHD), Alzheimer’s disease (AD) and Down syndrome.

News

Stefan Rehnmark (Principal Scientist, Gabather AB )

Published 4 years ago

Gabather AB completes phase 1 clinical study - Press release

Press release 2019-04-25

Gabather successfully completes phase 1a study of clinical candidate GT-002 Gabather AB reports today that the clinical phase 1 study in healthy volunteers with single ascending doses (SAD study) of GT-002 has been successfully completed. No drug-related adverse events have been reported and the preliminary conclusion is that the drug is safe and well tolerated, and that the pharmacokinetic properties of GT-002 is very promising. The final study report containing all safety data and a final evaluation of the pharmacokinetic results will be available to the company in June 2019.

The completion of the phase 1 study is a major milestone in the Company's development of the lead clinical candidate, GT-002, towards further studies in patients. The results that have been generated in the study will form the basis for the planning and implementation of the subsequent clinical studies including Multiple Ascending Dose (MAD) studies in which GT-002 will be given repeatedly for a limited time to evaluate safety and pharmacokinetics. A so-called "Proof-of-concept" (PoC) study in patients is planned where valuable data will be collected regarding the efficacy of GT-002 on CNS disorders either as a separate study or in combination with the MAD study.

Details about the phase 1 SAD study can be found in the following link: www.clinicaltrials.gov/ct2/show/NCT03817346?term=gabather&rank=1

Gabather AB

Michael Robin Witt,

CEO E-mail: mrw@gabather.com